LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, reported that as of the close of the market on July 24, 2009, CytRx is in compliance with all NASDAQ listing qualifications after its consolidated closing bid price exceeded $1.00 for 10 consecutive days meeting the requirement of NASDAQ Marketplace Rule 4310(c)(8)(D).
